<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993823</url>
  </required_header>
  <id_info>
    <org_study_id>G238OTIII/11IA01</org_study_id>
    <nct_id>NCT01993823</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double-blind, Parallel Group, Active Treatment-controlled Study Assessing the Safety and Efficacy of G238 Compared to Clotrimazole 1% Otic Solution in Patients With Otomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salvat</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salvat</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of G238 for the treatment of
      otomycosis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects With a Complete Response to Treatment</measure>
    <time_frame>Day 24</time_frame>
    <description>Efficacy will be assessed primarily by evaluation of the fungal culture, and the sum of signs and symptom scores (pruritus, otalgia, otorrhea and aural fullness obstruction to be scored as 0=absent; 1= mild; 2=moderate; 3=severe). The primary efficacy variable is the proportion of subjects with a negative culture for fungus, AND a signs and symptom score of 0 on Day 24.
Response to the study treatment was classed according to the following definitions:
Complete response: Negative fungal culture or presumed eradication on day 24, and sum score for signs and symptoms = 0 on day 24.
Partial response: Negative culture or presumed eradication on day 24, and sum score for signs and symptoms = 1 or 2 on day 24.
No response: Positive culture on day 24 or negative culture or presumed eradication and sum score for signs and symptoms &gt; 2 on day 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Signs/ Symptoms</measure>
    <time_frame>2 weeks and 4 weeks</time_frame>
    <description>The secondary efficacy variables include:
Proportion of subjects with signs and symptoms score of &quot;0&quot; at Day 15
Proportion of subjects with signs and symptoms score of &quot;0&quot; at Day 24
Proportion of subjects with a negative culture for fungus or presumed eradication (mycological cure) on Day 24.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mycological Study</measure>
    <time_frame>Day 24</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Otomycosis</condition>
  <arm_group>
    <arm_group_label>G238</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five drops into the ear canal twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clotrimazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Five drops into the ear canal twice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G238</intervention_name>
    <description>Five drops into the ear canal twice daily for 14 days</description>
    <arm_group_label>G238</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole</intervention_name>
    <description>Five drops into the ear canal twice daily for 14 days</description>
    <arm_group_label>Clotrimazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older.

          -  Clinical diagnosis of otomycosis where topical treatment is indicated.

        Exclusion Criteria:

          -  Other ear diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laboratorios SALVAT, S.A.</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <results_first_submitted>December 21, 2016</results_first_submitted>
  <results_first_submitted_qc>December 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2017</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otomycosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>ENT Mexican sites</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>G238</title>
          <description>Five drops into the ear canal twice daily for 14 days
G238: Five drops into the ear canal twice daily for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Clotrimazole</title>
          <description>Five drops into the ear canal twice daily for 14 days
Clotrimazole: Five drops into the ear canal twice daily for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Requested by the patient</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population: Randomized patients who had at least one efficacy evaluation after starting treatment</population>
      <group_list>
        <group group_id="B1">
          <title>G238</title>
          <description>Five drops into the ear canal twice daily for 14 days
G238: Five drops into the ear canal twice daily for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Clotrimazole</title>
          <description>Five drops into the ear canal twice daily for 14 days
Clotrimazole: Five drops into the ear canal twice daily for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="89"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="174"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" spread="15.8"/>
                    <measurement group_id="B2" value="39.8" spread="13.0"/>
                    <measurement group_id="B3" value="40.8" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With a Complete Response to Treatment</title>
        <description>Efficacy will be assessed primarily by evaluation of the fungal culture, and the sum of signs and symptom scores (pruritus, otalgia, otorrhea and aural fullness obstruction to be scored as 0=absent; 1= mild; 2=moderate; 3=severe). The primary efficacy variable is the proportion of subjects with a negative culture for fungus, AND a signs and symptom score of 0 on Day 24.
Response to the study treatment was classed according to the following definitions:
Complete response: Negative fungal culture or presumed eradication on day 24, and sum score for signs and symptoms = 0 on day 24.
Partial response: Negative culture or presumed eradication on day 24, and sum score for signs and symptoms = 1 or 2 on day 24.
No response: Positive culture on day 24 or negative culture or presumed eradication and sum score for signs and symptoms &gt; 2 on day 24.</description>
        <time_frame>Day 24</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>G238</title>
            <description>Five drops into the ear canal twice daily for 14 days
G238: Five drops into the ear canal twice daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole</title>
            <description>Five drops into the ear canal twice daily for 14 days
Clotrimazole: Five drops into the ear canal twice daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With a Complete Response to Treatment</title>
          <description>Efficacy will be assessed primarily by evaluation of the fungal culture, and the sum of signs and symptom scores (pruritus, otalgia, otorrhea and aural fullness obstruction to be scored as 0=absent; 1= mild; 2=moderate; 3=severe). The primary efficacy variable is the proportion of subjects with a negative culture for fungus, AND a signs and symptom score of 0 on Day 24.
Response to the study treatment was classed according to the following definitions:
Complete response: Negative fungal culture or presumed eradication on day 24, and sum score for signs and symptoms = 0 on day 24.
Partial response: Negative culture or presumed eradication on day 24, and sum score for signs and symptoms = 1 or 2 on day 24.
No response: Positive culture on day 24 or negative culture or presumed eradication and sum score for signs and symptoms &gt; 2 on day 24.</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No-response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Signs/ Symptoms</title>
        <description>The secondary efficacy variables include:
Proportion of subjects with signs and symptoms score of “0” at Day 15
Proportion of subjects with signs and symptoms score of “0” at Day 24
Proportion of subjects with a negative culture for fungus or presumed eradication (mycological cure) on Day 24.</description>
        <time_frame>2 weeks and 4 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>G238</title>
            <description>Five drops into the ear canal twice daily for 14 days
G238: Five drops into the ear canal twice daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole</title>
            <description>Five drops into the ear canal twice daily for 14 days
Clotrimazole: Five drops into the ear canal twice daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Signs/ Symptoms</title>
          <description>The secondary efficacy variables include:
Proportion of subjects with signs and symptoms score of “0” at Day 15
Proportion of subjects with signs and symptoms score of “0” at Day 24
Proportion of subjects with a negative culture for fungus or presumed eradication (mycological cure) on Day 24.</description>
          <population>ITT</population>
          <units>percentage of patient</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Signs and symptoms score 0 at Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.55"/>
                    <measurement group_id="O2" value="77.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Signs and symptoms score 0 at Day 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.83"/>
                    <measurement group_id="O2" value="86.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mycological cure at Day 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.63"/>
                    <measurement group_id="O2" value="97.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mycological Study</title>
        <time_frame>Day 24</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety analysis was conducted on the safety population (SAF), i.e. the population that includes all the randomised subjects who took at least one dose of the trial drug and had a safety evaluation.</desc>
      <group_list>
        <group group_id="E1">
          <title>G238</title>
          <description>Five drops into the ear canal twice daily for 14 days
G238: Five drops into the ear canal twice daily for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Clotrimazole</title>
          <description>Five drops into the ear canal twice daily for 14 days
Clotrimazole: Five drops into the ear canal twice daily for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor does not object to publication by Institution of the results of the Trial based on information collected or generated by Institution, whether or not the results are favorable to the Sponsor Drug. However, to ensure against inadvertent disclosure of Confidential Information or unprotected Inventions, Institution will provide Sponsor an opportunity to review any proposed publication or other type of disclosure before it is submitted or otherwise disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Enrique Jimenez, Medical Director</name_or_title>
      <organization>Laboratorios SALVAT</organization>
      <phone>+39933946470</phone>
      <email>ejimenezv@salvatbiotech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

